التفاصيل البيبلوغرافية
| العنوان: |
Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated Permanent Neonatal Diabetes. |
| المؤلفون: |
Bowman, Pamela, Mathews, Frances, Barbetti, Fabrizio, Shepherd, Maggie H., Sanchez, Janine, Piccini, Barbara, Beltrand, Jacques, Letourneau-Freiberg, Lisa R., Polak, Michel, Greeley, Siri Atma W., Rawlins, Eamon, Babiker, Tarig, Thomas, Nicholas J., De Franco, Elisa, Ellard, Sian, Flanagan, Sarah E., Hattersley, Andrew T., Mohsin, Fauzia, Cummings, Elizabeth, LeGault, Laurent |
| المصدر: |
Diabetes Care; Jan2021, Vol. 44 Issue 1, p35-42, 8p |
| مصطلحات موضوعية: |
METABOLIC regulation, GLYCEMIC control, ATTENTION-deficit hyperactivity disorder, NEURODEVELOPMENTAL treatment, DIABETES, RESEARCH, GENETIC mutation, RESEARCH methodology, POTASSIUM, HYPOGLYCEMIC agents, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, RESEARCH funding, LONGITUDINAL method |
| مصطلحات جغرافية: |
ITALY |
| مستخلص: |
Objective: ABCC8 mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder neurological features than those with KCNJ11-PNDM. However, these studies were short-term and included combinations of ABCC8-PNDM and ABCC8-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM.Research Design and Methods: We studied all 24 individuals with ABCC8-PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before May 2010. Data on glycemic control, sulfonylurea dose, adverse effects including hypoglycemia, and neurological features were analyzed using nonparametric statistical methods.Results: Long-term data were obtained for 21 of 24 individuals (median follow-up 10.0 [range 4.1-13.2] years). Eighteen of 21 remained on sulfonylureas without insulin at the most recent follow-up. Glycemic control improved on sulfonylureas (presulfonylurea vs. 1-year posttransfer HbA1c 7.2% vs. 5.7%, P = 0.0004) and remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, P = 0.04), n = 16. Relatively high doses were used (1-year vs. 10-year dose 0.37 vs. 0.25 mg/kg/day glyburide, P = 0.50) without any severe hypoglycemia. Neurological features were reported in 13 of 21 individuals; these improved following sulfonylurea transfer in 7 of 13. The most common features were learning difficulties (52%), developmental delay (48%), and attention deficit hyperactivity disorder (38%).Conclusions: Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic control. Overt neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid genetic testing to guide appropriate treatment and neurodevelopmental assessment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder